SCHEMBL2095584

SCHEMBL2095584

OCOc1ccccc1C(F)(F)F

nearest known ligand 0.53

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
RXRA P19793 1/20 0.53
RXRB P28702 1/20 0.53
RXRG P48443 1/20 0.53
MRGPRX4 Q96LA9 1/20 0.49
PPARG P37231 1/20 0.45
NOTUM Q6P988 1/20 0.44
MCL1 Q07820 1/20 0.42
ENPP2 Q13822 3/20 0.41
IDO1 P14902 2/20 0.41
L3MBTL1 Q9Y468 1/20 0.41
LTA4H P09960 1/20 0.41
PTGS2 P35354 1/20 0.41
SSTR4 P31391 2/20 0.41
SSTR1 P30872 1/20 0.40
RBP4 P02753 1/20 0.40
DRD2 P14416 1/20 0.40
FAAH O00519 1/20 0.39
BCHE P06276 1/20 0.39
ACHE P22303 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2090880 0.84 AR (0.54) RXRARXRBRXRGMRGPRX4PPARG
SCHEMBL2097943 0.82 RXRA (0.49) RXRARXRBRXRGMRGPRX4PPARG
SCHEMBL28060228 0.81 RXRA (0.50) RXRARXRBRXRGMRGPRX4PPARG
SCHEMBL5698974 0.81 RXRA (0.50) RXRARXRBRXRGMRGPRX4PPARG
SCHEMBL8955969 0.80 ALDH1A1 (0.52) RXRARXRBRXRGMRGPRX4MCL1
SCHEMBL9515076 0.79 ALDH1A1 (0.55) RXRARXRBRXRGL3MBTL1
SCHEMBL11840784 0.79 RXRA (0.49) RXRARXRBRXRGMRGPRX4PPARG
SCHEMBL21722981 0.79 RXRA (0.49) RXRARXRBRXRGMRGPRX4PPARG
SCHEMBL31035275 0.79 ALDH1A1 (0.50) RXRARXRBRXRGMRGPRX4L3MBTL1
SCHEMBL6946500 0.79 ALDH1A1 (0.50) RXRARXRBRXRGMRGPRX4L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8163753-B2 2-(4-(4-(4-chlorophenyl)oxazol-2-yl)phenoxymethyl)-2-methyl-6-nitro-2,3-dihydroimidazo[2,1-b]oxazole; bactericide; excellent bactericidal action against Mycobacterium tuberculosis, multi-drug-resistant Mycobacterium tuberculosis, and atypical acid-fast bacteria OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2012-04-24 US disclosed
EP-1678185-B1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMA CO LTD (JP) 2008-10-08 EP disclosed
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis OTSUKA PHAMACEUTICAL CO., LTD. (JP) 2008-05-22 US disclosed
EP-1678185-A1 2,3-DIHYDRO-6-NITROIMIDAZO [2,1-B] OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-07-12 EP disclosed
WO-2005042542-A1 2,3-DIHYDRO-6-NITROIMIDAZO (2,1-B) OXAZOLE COMPOUNDS FOR THE TREATMENT OF TUBERCULOSIS OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-05-12 WO disclosed
EP-0509446-B1 Preparation of 3,5-diaminobenzotrifluoride OCCIDENTAL CHEM CO (US) 1995-09-27 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080119478-A1 2,3-Dihydro-6-Nitroimidazo (2,1-b) Oxazole Compounds for the Treatment of Tuberculosis NR2C2, NR0B2, NR4A2 RXRA 179/4885RXRB 138/4885RXRG 289/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.